Patents by Inventor Heidi A. Lane

Heidi A. Lane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES
    Publication number: 20130059877
    Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
    Type: Application
    Filed: February 23, 2012
    Publication date: March 7, 2013
    Inventors: Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood
  • TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES
    Publication number: 20120283285
    Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
    Type: Application
    Filed: July 11, 2012
    Publication date: November 8, 2012
    Inventors: Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood
  • TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES
    Publication number: 20120214774
    Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
    Type: Application
    Filed: February 23, 2012
    Publication date: August 23, 2012
    Inventors: Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20120129881
    Abstract: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.
    Type: Application
    Filed: August 26, 2011
    Publication date: May 24, 2012
    Inventors: Gregory Burke, Heidi Lane, Ronald Richard Linnartz, Richard William Versace
  • PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR
    Publication number: 20110301184
    Abstract: A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.
    Type: Application
    Filed: August 11, 2011
    Publication date: December 8, 2011
    Applicant: NOVARTIS AG
    Inventor: Heidi Lane
  • NON-NEUROENDOCRINE CANCER THERAPY
    Publication number: 20110195072
    Abstract: The present invention provides a method of selecting subjects suffering or being predisposed to suffering from a proliferative disease in non-neuroendocrine tissues for treatment with a Ret inhibitor. The present invention also provides Ret inhibitors as medicaments for subjects suffering or being predisposed to suffering from a proliferative disease in non-neuroendocrine tissues.
    Type: Application
    Filed: September 10, 2007
    Publication date: August 11, 2011
    Inventors: Anne Boulay, Madlaina Breuleux, Nancy Hynes, Heidi A. Lane
  • TUBEROUS SCLEROSIS TREATMENT
    Publication number: 20100305150
    Abstract: Rapamycin derivatives for use in the treatment of neurocutaneous disorders.
    Type: Application
    Filed: January 31, 2007
    Publication date: December 2, 2010
    Inventors: William Berg, John Benedetto, Ingrid Elmroth, Heidi Lane, David Lebwohl, William Sellers, Michael Stumm
  • p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
    Patent number: 7749698
    Abstract: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: July 6, 2010
    Assignee: Novartis AG
    Inventors: Iwan Beuvink, Anne Boulay, Heidi Lane, Terence O'Reilly, George Thomas
  • PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR
    Publication number: 20090105285
    Abstract: A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.
    Type: Application
    Filed: May 9, 2007
    Publication date: April 23, 2009
    Applicant: NOVARTIS AG
    Inventor: Heidi Lane
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20090098137
    Abstract: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.
    Type: Application
    Filed: April 5, 2007
    Publication date: April 16, 2009
    Applicant: NOVARTIS AG
    Inventors: Gregory Burke, Heidi Lane, Ronald Richard Linnartz, Richard William Versace
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20090099103
    Abstract: The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: April 4, 2007
    Publication date: April 16, 2009
    Applicant: NOVARTIS AG.
    Inventors: Gregory Burke, Giorgio Caravatti, Heidi lane, Ronald richard Linnartz, Richard William Versace
  • Combination of Mtor Inhibitor and Antipolate Compound
    Publication number: 20090012105
    Abstract: Use of a combination of an mTOR inhibitor and an antifolate compound.
    Type: Application
    Filed: January 12, 2008
    Publication date: January 8, 2009
    Applicant: NOVARTIS AG
    Inventors: Heidi Lane, Terence O'Reilly
  • BIOMARKERS FOR SENSITIVITY OF PROLIFERATIVE DISEASES TO MTOR INHIBITORS
    Publication number: 20080214596
    Abstract: Disclosed is a method for determining the sensitivity of a proliferate disease in a subject to treatment with an mTOR inhibitor, comprising determining the level of expression and/or phosphorylation state of S6 in a sample derived from the subject, as well as related methods of treatment and uses.
    Type: Application
    Filed: May 13, 2008
    Publication date: September 4, 2008
    Inventors: Anne Boulay, Heidi Lane, Sauveur-Michel Maira, Terence O' Reilly
  • Combination Of Organic Compounds
    Publication number: 20080200486
    Abstract: The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound, and b) an mTOR kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: July 19, 2006
    Publication date: August 21, 2008
    Inventors: Heidi Lane, Paul W. Manley
  • P53 Wild-Type as Biomarker for the Treatment with Mtor Inhibitors in Combination With a Cytotoxic Agent
    Publication number: 20080194613
    Abstract: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.
    Type: Application
    Filed: February 22, 2005
    Publication date: August 14, 2008
    Inventors: Iwan Beuvink, Anne Boulay, Heidi Lane, Terence O'Reilly, George Thomas
  • Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
    Publication number: 20080085902
    Abstract: The present invention relates to a combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis. The patient is treated with a VEGF inhibitor compound; and one or more chemotherapeutic agents.
    Type: Application
    Filed: September 23, 2004
    Publication date: April 10, 2008
    Inventors: Guido Bold, Josef Bernhard Brueggen, Jerry Min-Jian Huang, Frederick Ray Kinder, Heidi Lane, Elisabeth Jeanne Latour, Paul W. Manley, Jeanette Marjorie Wood
  • Biomarkers for sensitivity of proliferative diseases to mtor inhibitors
    Publication number: 20070167478
    Abstract: Disclosed is a method for determining the sensitivity of a proliferate disease in a subject to treatment with an mTOR inhibitor, comprising determining the level of expression and/or phosphorylation state of S6 in a sample derived from the subject, as well as related methods of treatment and uses.
    Type: Application
    Filed: December 21, 2004
    Publication date: July 19, 2007
    Inventors: Anne Boulay, Heidi Lane, Sauveur-Michel Maira, Terence O'Reilly
  • Cancer treatment
    Publication number: 20040147541
    Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
    Type: Application
    Filed: January 27, 2004
    Publication date: July 29, 2004
    Inventors: Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood